Today's Date: May 11, 2021
Student-Led Startup Skin Releaf Takes USD 25,000 Top Prize in Standard Chartered 2021 Women in Tech Incubator Competition   •   National Geographic Documentary Films Partners With Acclaimed Director Dawn Porter in Search of Justice and Peace 100 Years Afte   •   EquityPlus Completes "4% Floor" $16 Million Bond Sale To Finance Senior Citizen Affordable Housing And Community Wellness Center   •   Joint statement on the 5th anniversary of Canada's full support for the United Nations Declaration on the Rights of Indigenous P   •   MAËLYS Receives Significant Investment from Norwest    •   AEO Inc. to Report First Quarter 2021 Results on May 26th   •   Leading DTC Bridal Brand Azazie Launches Size Inclusive Shapewear   •   Cadence13 Partners with Globally Renowned Thought Leader, Bestselling Author, and Activist Glennon Doyle for First-Ever Podcast   •   Commvault Celebrates Inclusion of 16 Global Executives to CRN's 2021 Women of the Channel List   •   Accenture and Shiseido Establish Joint Venture to Accelerate Shiseido’s Digital Transformation   •   Survey Reveals 8 Out Of 10 Asian Americans Say They Are Discriminated Against And 77% Do Not Feel Respected In The U.S.   •   Paway Celebrates Dog Moms Throughout The Month Of May With Their "Best Dog Mom Challenge"   •   Global War on Terrorism Memorial Foundation Gets Support From MISSION BBQ American Heroes Cup Campaign   •   Unilever's Second Annual Day of Service Gets Sweeter at Vaccine Locations Across the Country   •   Wells Fargo Joins OneTen Coalition to Hire, Upskill and Advance Black and African American Talent in the U.S.   •   Indigenous Services Canada announces 2021 recipients of the Awards of Excellence in Nursing   •   BlackNorth Initiative Sponsoring Lori-Ann Green-Walker, Part of the 6th Cohort of the ESG Competent Boards Certificate Program   •   Miami Based Black Advertisement Agency Receives Multiple 27th Annual Communicator Awards From the Academy of Interactive and Vis   •   Susan G. Komen® Welcomes Eight New Leaders in Healthcare, Marketing and Business Operations to Board of Directors   •   Statement - Minister of Veterans Affairs marks National Nursing Week
Bookmark and Share

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemi

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

- Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation

PR Newswire

LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MMUT). The study results were recently highlighted in a poster presentation at the American College of Medical Genetic and Genomics (ACMG) Annual Clinical Genetics Meeting.

MMA is a rare genetic disorder that can be caused by mutations in several genes, with the MMUT genetic mutation being the most common. Mutations in this gene, which provides instructions for making the MMUT enzyme, prevents the body from properly processing certain fats and proteins and can lead to the toxic buildup of methylmalonic acid and other disease-causing metabolites. Patients with severe MMA may present with symptoms as early as at birth including poor feeding, vomiting, hypotonia, hypothermia, respiratory distress and progressive encephalopathy. They are also at increased risk of neurological symptoms, failure to thrive, intellectual disability, severe infections and progressive renal insufficiency. There are currently no approved treatment options targeting the underlying cause of the disease. Current standard of care for MMA includes protein diet management and liver transplantation.

The retrospective non-interventional natural history study collected data via chart review from 18 patients diagnosed with severe MMA by newborn screening, including patients managed medically from birth to three years old (cohort 1) and pediatric-age recipients of liver transplant (cohort 2). Patients in cohort 2 were observed for the one-year period before liver transplantation and up to three years following the procedure. Results showed a significant and sustained decrease in methylmalonic acid levels post-transplantation compared to baseline levels. While levels did not approach normalization, there was an apparent reduction in variability, a potential indication of improved metabolic stability. Results indicate there were no significant differences in MMA- or transplant-related emergency room (ER) visits, stays or hospitalizations among patients pre- and post-transplantation up to three years. However, interpretation of the data on healthcare use was limited, as data for two and three years post-transplant were available for only one or two patients.

"Findings from this study are consistent with published clinical data supporting liver transplantation as an increasingly utilized therapeutic option for severe MMA patients while highlighting its limitations as an invasive and high-risk procedure that presents lifelong health considerations for patients," said Daniel Gruskin, M.D., senior vice president and head of clinical development at LogicBio. "These data help provide a better understanding of the natural progression and burden of this devastating rare disease and will help inform our clinical trial design and endpoint selection for future studies of our lead program LB-001. We also anticipate that results from a prospective natural history study we are initiating will provide important additional information about the disease course and position us to provide optimal support to families affected by MMA."

A link to the ACMG meeting study presentation is available under the "Events and Presentations" section of LogicBio's website, found here: https://investor.logicbio.com/events-and-presentations/events.

About Methylmalonic Acidemia (MMA)

Methylmalonic acidemia, or MMA, is a rare and life-threatening genetic disorder, affecting 1 in 25,000 to 50,000 newborns. In the most common form of MMA, a mutation in a gene called MMUT prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no cure for MMA. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can cause permanent neurocognitive damage.

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit https://www.logicbio.com/.

Media Contacts:

Bill Berry

Berry & Company Public Relations

W: 212-253-8881

C: 917-846-3862

bberry@berrypr.com

Jenna Urban

Berry & Company Public Relations

W: 212-253-8881

C: 203-218-9180

jurban@berrypr.com

Investor Contacts:

Matt Lane

Gilmartin Group

617-901-7698

matt@gilmartinir.com

 

Cision View original content:http://www.prnewswire.com/news-releases/logicbio-announces-presentation-of-retrospective-study-of-disease-course-in-pediatric-patients-with-severe-methylmalonic-acidemia-301282494.html

SOURCE LogicBio Therapeutics, Inc.



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News